Clinical Trial Search

Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment.(Motor Scores) — 0; 3; 0; 0 Participants

Primary: Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample — 6.49; 6.46; 6.07; 6.02 VZV genome copies per sample

Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)

Primary: Reporting of Adverse Events — 9 participants

Primary: Number of Participants Reported Adverse Events (AEs), Serious Adverse Events (SAEs) — 6; 6; 0; 0 Participants

Primary: Percentage of Participants Without Sore Throat According to TSS Score — 84.35; 73.21; 13.91; 17.86 percentage of participants — p=0.028

Primary: Duration of Episode (DOE) Was Measured in Hours (Using the Science 37 Platform), of a Single Treated Herpes Labialis (HL) Lesion — 66.5; 73.6 Hours — p=0.716

Primary: Percentage of Participants With Healing by Day 8 — 194 Participants

Primary: Lesion Healing — 107.47; 110.08; 112.41 hours

Primary: Proportion of Subjects Who Experience a New Cold Sore Outbreak That Proceeds to the Lesion Stage. Of Those Subjects That Take Study Medication (Experience a New Emerging…

Primary: Safety and Tolerability of a Single-dose of Famciclovir in Part A of the Study. — 0; 2; 1; 2 participants